

## Numbers undone by Covid 19 disturbances...

Q4FY20 revenues de-grew 4.1% YoY to ₹ 109 crore impacted by loss of few business days due to Covid-19 related disturbances. EBITDA margins posted a steep decline of 1100 bps to 2.3% (13.4% in Q4FY19) due to negative operational leverage. Subsequently, EBITDA declined 83.4% YoY to ₹ 2.5 crore. Despite higher other income, higher tax outgo (₹ 19 crore vs ₹ 3.6 crore in Q4FY19) contributed towards registering a loss of ₹ 17.1 crore for the quarter. On a full year basis, revenues grew 5.6% to ₹ 487 crore with EBITDA margins contracting 104 bps to 16.8% mainly due to lower gross margins whereas EBITDA remained flat at ₹ 82 crore.

## Market leader in fast growing joint replacement surgeries

Rapid ageing, greater life expectancy, lack of exercise as well as altered lifestyles are driving the incidences of osteoarthritis among Indians. Knee replacement surgery in India has been growing in double digits over the years. It is expected to emerge as the fourth most common cause of physical disability in India in the next decade. Shalby is a market leader in the procedure of arthroplasty (source: F&S Report). The company has ~15% market share of all joint replacement surgeries conducted by organised private corporate hospitals in India. It has performed more than one lakh joint replacements till date. Led by renowned orthopaedic surgeon Dr Shah, the company has achieved strong brand recall in joint replacement surgeries, especially in Gujarat.

## No legacy debt issues but EBITDA concentration still high...

Shalby has a debt free balance sheet, a unique feature among hospital chains, which are on expansion mode. Despite continuous expansion in the past decade, the company has remained debt free owing to its asset light model approach and persistent free cash flow generation from legacy hospitals in Ahmedabad owing to brand stickiness. That said, when it comes to EBITDA generation, the company is still heavily dependent upon four main hospitals (+6 years) that accounted for +80% of FY20 EBITDA.

## Valuation & Outlook

Like other hospitals, Q4 performance was impacted by Covid 19. This is likely to continue for some time and more so for Shalby where significant traction is from elective surgeries (read arthroplasty) although management remains hopeful of early recovery. Arthroplasty continues to dominate its revenue pie although it has been seeing greater traction in other specialities as well. Leverage free b/s, strong margins and free cash flow generation are some of the strongholds. However, skewed margins, weak return ratios are still major concerns. We value the company on an SOTP basis by valuing hospitals (above six years) at 6x FY22E EV/EBITDA and hospitals (below six years) at 1x FY22E EV/sales. We arrive at an SOTP target price of ₹ 70. Ramp up in below six years hospitals will be key to watch for re-rating.

### Key Financial Summary

₹Crore	FY19	FY20	FY21E	FY22E	CAGR FY20-22E (%)
Revenues	461.0	486.9	383.4	543.9	5.7
EBITDA	82.2	81.7	48.6	98.0	9.5
EBITDA margins (%)	17.8	16.8	12.7	18.0	
Net Profit	31.7	27.6	7.9	43.5	25.5
EPS (₹)	2.9	2.6	0.7	4.0	
PE (x)	23.5	27.0	93.9	17.1	
M.Cap/ Revenues (x)	1.6	1.5	1.9	1.4	
EV to EBITDA (x)	9.0	9.4	15.7	8.0	
RoCE (%)	6.8	7.2	1.8	7.0	
ROE (%)	4.1	3.5	1.0	5.2	

Source: ICICI Direct Research; Company

## SHALBY

MULTI-SPECIALTY  
HOSPITALS

### Particulars

Particular	Amount
Market Capitalisation	₹745 crore
Debt (FY 20)	₹49 crore
Cash (FY 20)	₹29 crore
EV	₹765 crore
52 week H/L	124/40
Equity capital	₹108.0 crore
Face value	₹10

### Key Highlights

- Covid-19 impacted Q4 performance
- Leverage free balance sheet, strong margins, free cash flow generation are some strongholds
- The company is still heavily dependent upon four main hospitals (+6 years) for EBITDA generation
- Change from BUY to HOLD with target price of ₹ 70

### Research Analyst

Siddhant Khandekar  
siddhant.khandekar@icicisecurities.com

Mitesh Shah, CFA  
mitesh.shah@icicisecurities.com

Sudarshan Agarwal  
sudarshan.agarwal@icicisecurities.com

## Exhibit 1: Variance Analysis

	Q4FY20	Q4FY19	Q3FY20	YoY (%)	QoQ (%)	Comments
Revenue	108.9	113.5	120.8	-4.1	-9.9	Decline mainly due loss of 10 days of business amid lockdown
Raw Material Expenses	12.5	15.2	10.8	-18.0	15.6	
Employee Expenses	16.1	17.1	16.1	-5.7	0.4	
Other Expenditure	77.8	66.0	72.1	17.8	7.9	
Total Operating Expenditure	106.4	98.3	98.9	8.2	7.5	
EBITDA	2.5	15.2	21.9	-83.4	-88.5	Sharp decline due to ₹ 7-8 crore of EBITDA loss due to lockdown and negative operational leverage
EBITDA (%)	2.3	13.4	18.1	-1105 bps	-1578 bps	
Interest	1.7	2.5	1.3	-31.2	30.3	
Depreciation	9.0	7.9	8.9	14.1	1.6	
Other income	10.1	2.1	2.1	391.8	381.0	
PBT before EO	1.9	6.8	13.8	-72.3	-86.3	
Less: Exceptional Items	0.0	0.0	0.0	0.0	0.0	
PBT	1.9	6.8	13.8	-72.3	-86.3	
Tax	19.0	3.6	5.6	432.9	238.7	Sharp increase due to deferred tax adjustments
Minority Interest	0.0	0.0	0.0	0.0	0.0	
Adj. Net Profit	-17.1	3.3	8.1	PL	PL	Delta vis-à-vis EBITDA mainly due to higher tax outgo amid tax revision

Source: ICICI Direct Research

## Exhibit 2: Change in Estimates

	FY21E			FY22E			Comments
(₹ Crore)	Old	New	% Change	Old	New	% Change	
Revenue	559.0	383.4	-31.4	636.3	543.9	-14.5	Changed amid Covid 19
EBITDA	112.1	48.6	-56.7	134.0	98.0	-26.9	
EBITDA Margin (%)	20.0	12.7	-737 bps	21.1	18.0	-304 bps	Changed amid Covid 19
PAT	56.4	7.9	-85.9	72.9	43.5	-40.4	
EPS (₹)	5.2	0.7	-85.9	6.8	4.0	-40.8	Changed amid Covid 19

Source: ICICI Direct Research

## Conference Call Highlights

- Covid-19 related commentary
  - Revenue impact- 10 days loss of business
  - EBITDA was impacted by ₹ 7-8 crore amid negative operational leverage
  - Capex has been deferred by around six months with Nashik project to be completed in FY23 and Mumbai in FY24
  - The company has taken measures such as pay cuts to reduce operational costs in Q1FY21
- Higher tax rate due to deferred tax adjustments
- Higher other expenses were on account of CSR costs
- The company has seen 60-80% drop in revenues in April-May period on account of delayed electives and reduced patient footfall. Despite this, the management expects to be EBITDA positive in Q1FY21
- The management expects occupancies to be back to pre-Covid levels from July-August, 2020
- The company has undertaken certain initiatives to facilitate revenue growth
  - Shalby care card – aimed at uninsured population, similar to a loyalty program to enhance customer stickiness with annual memberships at ₹ 2500 and ₹ 5000. The patient will be given free health check-up as per the card amount. Additionally, in-patient, out-patient and pharmacy discounts will be given as per the plan purchased. In-patient discount will not be applicable to patients opting for insurance re-imburements
  - Shalby Home care
  - Franchise model for arthroplasty
  - Medical devices foray through Mars Medical Devices Ltd. One-third cost of a joint operation (~₹ 180,000) is from the medical device
- FY20 ARPOB was at ₹ 30457 and ALOS (ex-daycare) at 4.22
- FY20 revenue share – arthroplasty: non arthroplasty - 45:55 split
  - Maturity based – > 6+ years: 47%, 4-6 years: 21%, 2-4 years: 28% and <2 years: 4%

## Exhibit 3: Quarterly Financials

(₹ crore)	Q 1FY 19	Q 2FY 19	Q 3FY 19	Q 4FY 19	Q 1FY 20	Q 2FY 20	Q 3FY 20	Q 4FY 20	YoY (%)	QoQ (%)
Total Operating Income	115.9	119.3	112.8	113.5	131.4	125.7	120.8	108.9	-4.1	-9.9
Raw Material Expenses	6.5	8.7	9.3	15.2	21.0	9.2	10.8	12.5	-18.0	15.6
% of Revenue	5.6	7.3	8.2	13.4	16.0	7.4	8.9	11.5	-195 bps	252 bps
Gross Profit	109.4	110.6	103.5	98.3	110.4	116.5	110.0	96.4	-1.9	-12.4
Gross Profit Margin (%)	94.4	92.7	91.8	86.6	84.0	92.6	91.1	88.5	195 bps	-252 bps
Employee Expenses	15.2	15.9	16.4	17.1	16.8	16.5	16.1	16.1	-5.7	0.4
% of Revenue	13.1	13.3	14.5	15.1	12.8	13.1	13.3	14.8	-25 bps	151 bps
Other Expenditure	69.5	71.9	67.5	66.0	64.2	72.0	72.1	77.8	17.8	7.9
% of Revenue	60.0	60.3	59.8	58.2	48.9	57.3	59.7	71.4	1325 bps	1175 bps
Total Expenditure	91.3	96.6	93.2	98.3	102.1	97.7	98.9	106.4	8.2	7.5
% of Revenue	78.7	80.9	82.6	86.6	77.7	77.7	81.9	97.7	1105 bps	1578 bps
EBITDA	24.6	22.8	19.6	15.2	29.4	28.0	21.9	2.5	-83.4	-88.5
EBITDA Margin (%)	21.3	19.1	17.4	13.4	22.3	22.3	18.1	2.3	-1105 bps	-1578 bps
Other Income	2.8	2.3	2.2	2.1	1.9	2.2	2.1	10.1	391.8	381.0
Interest	1.5	2.0	1.5	2.5	1.3	1.0	1.3	1.7	-31.2	30.3
Depreciation	8.3	8.4	8.6	7.9	8.9	9.2	8.9	9.0	14.1	1.6
PBT	17.7	14.6	11.8	6.8	21.1	20.0	13.8	1.9	-72.3	-86.3
Total Tax	5.6	11.1	-1.6	3.6	-2.5	7.1	5.6	19.0	432.9	238.7
Tax rate (%)	32.0	75.9	-13.2	52.2	-12.0	35.4	40.8	1005.5	NA	NA
PAT	12.0	3.5	13.4	3.3	23.6	12.9	8.1	-17.1	-623.6	-309.9
PAT Margin (%)	10.4	3.0	11.8	2.9	18.0	10.3	6.7	-15.7	PL	PL
EPS (₹)	1.1	0.3	1.2	0.3	2.2	1.2	0.8	-1.6		

Source: ICICI Direct Research, Company


## Company Background

Healthcare services under the brand 'Shalby' commenced in 1994 while actual incorporation happened in 2004. Led by Dr Vikram Shah, an orthopaedic surgeon with more than 25 years of professional experience, the company has grown from a single hospital to a chain of multi-specialty hospitals. Its first hospital, Vijay Shalby was established by Shalby Orthopaedic Hospital and Research Centre, one of the group entities, in 1994. Subsequently, SG Shalby and Vrundavan Shalby commenced operations in 2007 and 2011, respectively. From four hospitals in April 2012, the company has grown to 11 hospitals.

The company also has a network of 37 outpatient clinics across 11 states in India and abroad, which act as a separate medium to tap new patients. Internationally also, it has established a strong presence in Africa, Bangladesh and Cambodia with multiple out-patient clinics extending expert healthcare and wellness services to these countries.


The existing revenue mix between arthroplasty and other specialties is at ~45:55 (FY20). The total bed capacity was at 2012 with operational beds at 1200. The company employs over 4000 employees including more than 500 doctors. Shalby registered a blended ARPOB of ₹ 30457 and ALOS of 4.22 days (without day care procedures) in FY20.

Exhibit 4: Revenues to grow at CAGR of 6% over FY20-22E




Source: ICICI Direct Research, Company

Exhibit 5: EBITDA &amp; margins trend




Source: ICICI Direct Research, Company

Exhibit 6: Net profit &amp; margins trend



Source: ICICI Direct Research, Company

Exhibit 7: RoE &amp; RoCE trend



Source: ICICI Direct Research, Company

Exhibit 8: Valuation

Particulars	Valuation Matrix	Multiple (x)	EV (₹cr)
Above 6 years	EV/EBITDA	6.0	486
below 6 years	EV/Sales	1.0	297
EV			782
Net Debt FY22E (₹cr)			36.2
Minority Interest			0.6
Targeted MCap (₹cr)			746
No of shares (cr)			10.8
<b>Per Share Value (₹)</b>			<b>70</b>


Source: ICICI Direct Research, Company

Exhibit 9: Summary

	Revenues	Growth	EPS	Growth	P/E	V/EBITDA	RoE	RoCE
	(₹crore)	(%)	(₹)	(%)	(x)	(X)	(%)	(%)
FY 19	461	21.9	2.9	-19.2	23.5	9.0	4.1	6.8
FY 20	487	5.6	2.6	-12.8	27.0	9.4	3.5	7.2
FY 21E	383	-21.3	0.7	-71.3	93.9	15.7	1.0	1.8
FY 22E	544	41.9	4.0	448.0	17.1	8.0	5.2	7.0

Source: ICICI Direct Research, Company

Exhibit 10: Price chart



Source: ICICI Direct Research, Bloomberg

Exhibit 11: Shareholding Pattern

(in %)	Mar-19	Jun-19	Sep-19	Dec-19	Mar-20
Promoter	79.4	79.4	79.4	79.4	79.4
Others	20.6	20.6	20.6	20.6	20.6

Source: ICICI Direct Research, Company

## Financial Summary

Exhibit 12: Profit &amp; Loss (₹ crore)

Year-end March	FY19	FY20	FY21E	FY22E
Total Operating Income	461.0	486.9	383.4	543.9
Growth (%)	21.9	5.6	-21.3	41.9
Raw Material Expenses	41.2	53.6	46.0	67.8
Gross Profit	419.8	433.3	337.4	476.0
Gross Profit Margins (%)	91.1	89.0	88.0	87.5
Employee Expenses	64.6	65.5	51.7	72.9
Other Expenditure	273.0	286.1	237.1	305.2
Total Operating Expenditure	378.8	405.1	334.8	445.9
<b>EBITDA</b>	<b>82.2</b>	<b>81.7</b>	<b>48.6</b>	<b>98.0</b>
Growth (%)	4.1	-0.5	-40.6	101.7
Interest	8.3	5.4	5.4	5.4
Depreciation	33.2	36.0	36.5	37.4
Other Income	9.6	16.4	3.8	2.7
<b>PBT before Exceptional Items</b>	<b>50.4</b>	<b>56.7</b>	<b>10.6</b>	<b>57.9</b>
Less: Exceptional Items	0.0	0.0	0.0	0.0
PBT after Exceptional Items	50.4	56.7	10.6	57.9
Total Tax	18.7	29.1	2.6	14.5
PAT before MI	31.7	27.6	7.9	43.5
<b>PAT</b>	<b>31.7</b>	<b>27.6</b>	<b>7.9</b>	<b>43.5</b>
Growth (%)	-19.2	-12.8	-71.3	448.0
<b>EPS (Adjusted)</b>	<b>2.9</b>	<b>2.6</b>	<b>0.7</b>	<b>4.0</b>

Source: ICICI Direct Research

Exhibit 13: Cash Flow Statement (₹ crore)

Year-end March	FY19	FY20	FY21E	FY22E
Profit/(Loss) after taxation	41.0	36.6	7.9	43.5
Add: Depreciation & Amortization	33.2	36.0	36.5	37.4
Net Increase in Current Assets	-59.7	-28.6	30.4	-34.1
Net Increase in Current Liabilities	17.7	11.0	-6.3	24.1
Others	2.2	0.4	5.4	5.4
<b>CF from Operating activities</b>	<b>34.3</b>	<b>55.4</b>	<b>73.9</b>	<b>76.2</b>
Investments	-12.3	-1.6	0.0	20.0
(Purchase)/Sale of Fixed Assets	-31.3	-19.8	-60.0	-95.0
Others	8.9	-58.4	-4.7	-5.2
<b>CF from Investing activities</b>	<b>-34.8</b>	<b>-79.8</b>	<b>-64.7</b>	<b>-80.2</b>
Inc / (Dec) in Equity Capital	0.0	0.0	0.0	0.0
Dividend & Dividend tax	0.0	-6.5	0.0	-10.8
Other	-40.8	-15.0	-5.4	-5.4
<b>CF from Financing activities</b>	<b>-40.8</b>	<b>-21.5</b>	<b>-5.4</b>	<b>-16.2</b>
<b>Net Cash Flow</b>	<b>-41.3</b>	<b>-45.9</b>	<b>3.9</b>	<b>-20.1</b>
Cash and Cash Equivalent	115.9	74.6	28.7	32.6
<b>Cash</b>	<b>74.6</b>	<b>28.7</b>	<b>32.6</b>	<b>12.5</b>
<b>Free Cash Flow</b>	<b>3.0</b>	<b>35.6</b>	<b>13.9</b>	<b>-18.8</b>

Source: ICICI Direct Research

Exhibit 14: Balance Sheet (₹ crore)

Year-end March	FY19	FY20	FY21E	FY22E
Equity Capital	108.0	108.0	108.0	108.0
Reserve and Surplus	671.8	691.2	699.1	731.7
Total Shareholders funds	779.8	799.2	807.1	839.8
Total Debt	70.8	48.7	48.7	48.7
Deferred Tax Liability	9.3	17.8	18.1	18.5
Minority Interest	0.1	0.5	0.5	0.6
Other Non Current Liabilities	14.0	17.3	17.6	18.0
<b>Source of Funds</b>	<b>874.0</b>	<b>883.4</b>	<b>892.1</b>	<b>925.4</b>
Gross Block - Fixed Assets	756.0	772.6	782.6	802.6
Accumulated Depreciation	74.3	110.3	146.8	184.2
Net Block	681.7	662.3	635.8	618.4
Capital WIP	3.4	6.4	56.4	131.4
Goodwill	10.2	10.2	10.2	10.2
Fixed Assets	695.2	678.9	702.4	760.0
Investments	10.9	28.0	28.0	8.0
Other non-Current Assets	39.2	37.9	41.7	45.9
Deferred Tax Assets	11.3	16.0	17.6	19.3
Inventory	12.8	15.2	10.7	15.1
Debtors	81.4	94.9	67.7	96.0
Loans and Advances	23.0	0.0	0.0	0.0
Other Current Assets	0.0	67.0	68.4	69.7
Cash	74.6	28.7	32.6	12.5
Total Current Assets	191.8	205.9	179.3	193.4
Creditors	62.0	60.2	51.6	73.2
Provisions	0.7	5.4	6.0	6.6
Other Current Liabilities	11.8	17.7	19.4	21.4
Total Current Liabilities	74.5	83.2	77.0	101.1
Net Current Assets	117.3	122.6	102.4	92.2
<b>Application of Funds</b>	<b>874.0</b>	<b>883.4</b>	<b>892.1</b>	<b>925.4</b>

Source: ICICI Direct Research

Exhibit 15: Key Ratios (₹ crore)

Year-end March	FY19	FY20	FY21E	FY22E
<b>Per share data (₹)</b>				
Reported EPS	2.9	2.6	0.7	4.0
Cash EPS	2.3	1.7	0.7	3.0
BV per share	72.2	74.0	74.7	77.7
Cash per Share	6.9	2.7	3.0	1.2
Dividend per share	0.6	0.9	0.0	1.0
<b>Operating Ratios (%)</b>				
Gross Profit Margins	91.1	89.0	88.0	87.5
EBITDA margins	17.8	16.8	12.7	18.0
PAT Margins	6.9	5.7	2.1	8.0
Cash Conversion Cycle	25.5	37.4	25.5	25.5
Asset Turnover	0.6	0.6	0.5	0.7
EBITDA conversion Rate	41.8	67.7	152.2	77.8
<b>Return Ratios (%)</b>				
RoE	4.1	3.5	1.0	5.2
RoCE	6.8	7.2	1.8	7.0
RoIC	6.2	5.5	1.5	7.9
<b>Valuation Ratios (x)</b>				
P/E	23.5	27.0	93.9	17.1
EV / EBITDA	9.0	9.4	15.7	8.0
EV / Net Sales	1.6	1.6	2.0	1.4
Market Cap / Sales	1.6	1.5	1.9	1.4
Price to Book Value	1.0	0.9	0.9	0.9
<b>Solvency Ratios</b>				
Debt / EBITDA	0.9	0.6	1.0	0.5
Debt / Equity	0.1	0.1	0.1	0.1
Current Ratio	1.6	2.1	1.9	1.8

Source: ICICI Direct Research



## Exhibit 16: ICICI Direct universal Coverage (Healthcare)

Company	I-Direct Code	CMP (₹)	TP (₹)	Rating	M Cap (₹cr)	EPS (₹)				PE(x)				RoCE (%)				RoE (%)			
						FY19	Y20E	Y21E	Y22E	FY19	Y20E	Y21E	Y22E	Y19	Y20E	Y21E	Y22E	FY19	Y20E	Y21E	Y22E
Ajanta Pharma	AJAPHA	1452	1,730	Buy	12666	43.5	53.4	56.0	72.0	33.3	27.2	25.9	20.2	21.8	24.7	22.3	24.2	17.1	18.1	16.7	18.5
Alembic Pharma	ALEMPHA	947	875	Buy	17843	31.4	46.3	41.4	39.8	30.1	20.4	22.9	23.8	19.6	20.6	17.7	16.0	21.8	26.3	19.5	16.2
Aurobindo Pharma	AURPHA	783	920	Buy	45905	41.9	48.8	55.0	61.4	18.7	16.1	14.2	12.8	15.9	17.2	18.2	18.7	17.7	17.0	16.3	15.6
Biocon	BIOCON	381	390	Buy	45750	6.2	5.8	9.8	18.2	61.4	65.5	38.7	21.0	10.9	10.9	15.1	22.1	12.2	10.4	15.2	22.4
Cadila Healthcare	CADHEA	362	375	Hold	37065	18.1	14.3	17.5	20.9	20.0	25.3	20.7	17.3	13.0	10.6	12.1	13.4	17.8	12.9	14.1	14.9
Cipla	CIPLA	636	670	Buy	51295	18.6	19.2	23.0	30.2	34.2	33.1	27.6	21.0	10.9	12.0	13.0	15.4	10.0	9.8	10.8	12.6
Divi's Lab	DIVLAB	2305	2,355	Hold	61184	51.0	51.9	58.2	73.6	45.2	44.4	39.6	31.3	25.5	23.9	23.0	24.1	19.4	18.8	18.1	19.2
Dr Reddy's Lab	DRREDD	4006	4,615	Buy	66558	114.7	121.9	163.8	209.7	34.9	32.9	24.5	19.1	11.1	10.0	18.0	20.8	13.6	13.0	15.2	16.6
Glenmark Pharma	GLEPHA	409	340	Hold	11551	26.9	26.8	34.6	43.2	15.2	15.3	11.8	9.5	15.3	12.8	14.5	16.1	13.5	12.0	13.5	14.5
Hikal	HIKCHE	117	165	Buy	1444	8.4	8.1	10.8	13.8	14.0	14.5	10.9	8.5	14.3	13.0	14.2	15.7	13.6	12.2	14.2	15.6
Ipca Laboratories	IPCLAB	1616	1,900	Buy	20413	35.1	47.8	63.3	79.2	46.1	33.8	25.5	20.4	15.0	17.4	19.7	20.7	14.2	16.6	18.1	18.6
Jubilant Life	JUBLIF	647	550	Buy	10299	54.9	59.9	69.8	89.8	11.8	10.8	9.3	7.2	14.3	14.6	17.2	19.7	17.8	16.6	16.4	17.5
Lupin	LUPIN	914	930	Hold	41430	16.5	-12.7	25.6	38.7	55.3	-72.0	35.8	23.6	9.4	10.6	10.4	14.6	5.4	-4.6	8.5	11.6
Narayana Hrudayam	NARHRU	271	340	Buy	5546	2.9	6.4	-3.1	9.6	93.5	42.7	-88.4	28.2	7.7	11.0	0.0	14.2	5.5	11.4	-5.8	15.7
Natco Pharma	NATPHA	629	740	Buy	11446	35.4	25.3	23.9	22.4	17.8	24.8	26.3	28.1	21.3	14.0	12.9	11.3	18.5	12.2	10.7	9.3
Sun Pharma	SUNPHA	488	540	Buy	117109	15.9	16.8	18.4	24.5	30.8	29.1	26.6	19.9	10.3	10.0	10.3	12.4	9.2	8.9	8.9	10.8
Syngene Int.	SYNINT	378	390	Buy	15120	8.3	10.3	8.6	12.2	45.7	36.7	38.6	27.3	14.8	15.0	12.9	16.4	16.8	15.7	13.7	16.3
Torrent Pharmaceuticals	TORPHA	2543	2,475	Hold	43039	48.9	60.6	67.0	88.3	52.0	42.0	38.0	28.8	14.2	15.7	17.7	21.2	17.5	21.2	20.0	22.0
Shalby	SHALIM	69	70	Hold	745	2.9	2.6	0.7	4.0	23.5	27.0	93.9	17.1	6.8	7.2	1.8	7.0	4.1	3.5	1.0	5.2

Source: ICICI Direct Research, Bloomberg

## RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%;

Hold: -5% to 15%;

Reduce: -5% to -15%;

Sell: <-15%



Pankaj Pandey

Head – Research

[pankaj.pandey@icicisecurities.com](mailto:pankaj.pandey@icicisecurities.com)

ICICI Direct Research Desk,  
ICICI Securities Limited,  
1st Floor, Akruti Trade Centre,  
Road No 7, MIDC,  
Andheri (East)  
Mumbai – 400 093  
[research@icicidirect.com](mailto:research@icicidirect.com)

## ANALYST CERTIFICATION

We /I, Siddhant Khandekar, Inter CA, Mitesh Shah, CFA, Sudarshan Agarwal, PGDM (Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

## Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com)

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icicidirect.com](http://icicidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.